Fatima Z. Islam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fatima Z. Islam has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- James E. Dahlman
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA
4 shared publications - Beau Bosko Toskich
Division of Interventional Radiology, Mayo Clinic Florida, Jacksonville, Fla
3 shared publications Cory D. Sago
Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology and Emory University School of Medicine Atlanta GA 30332 USA
3 shared publications- Melissa P. Lokugamage
Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology and Emory University School of Medicine Atlanta GA 30332 USA
3 shared publications Zubao Gan
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA
3 shared publications- Brandon R. Krupczak
Wallace H. Coulter, Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA
2 shared publications
Latest Publications
- 20 June 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (12) , 6631-6635
Immediate percutaneous renal mass biopsy following cryoablation: validation of diagnostic performance and clinical outcomes
Objectives Image-guided thermal ablation is a guideline-supported treatment for small renal tumors. While biopsy is recommended, the optimal timing relative to ablation remains undefined. Pre-ablation biopsy may complicate ablation through hemorrhage, impaired target visualization, and potential tumor seeding. Post-cryoablation biopsy has been described in a small cohort of patients, but reproducibility has not been established. This study evaluated the diagnostic performance and clinical outcomes of renal mass biopsy performed immediately after cryoablation in a single session. Methods This retrospective, single-center study included patients who underwent image-guided percutaneous cryoablation followed by immediate post-ablation core needle biopsy, performed at operator discretion, between December 2018 and April 2025. After active or passive thaw and probe removal, at least two 18-gauge core biopsy samples were obtained per lesion using a coaxial needle. Specimens were formalin-fixed and reviewed by pathology. Outcomes included specimen adequacy, histopathologic diagnosis, adverse events, imaging response, and tumor recurrence or seeding. Follow-up imaging and labs were performed at 3 and 6 or 9 months, then annually. Results Twenty-six solid enhancing renal masses (mean size 2.5 cm, range 1.4–4.7 cm) in 24 patients were included. All biopsy specimens were diagnostic with histologic diagnoses including renal cell carcinoma (RCC, n = 19), oncocytoma (n = 6), and metanephric adenoma (n = 1), with RCC subtypes including clear cell, papillary, chromophobe, sarcomatoid, and mixed histology. Complications were limited to the immediate post-procedural period, with no delayed adverse events or chronic sequelae. All lesions demonstrated complete radiographic response on 3-month follow-up imaging. There were no cases of tumor recurrence or seeding observed over a median follow-up of 1,415 days. Conclusion Immediate post-cryoablation renal mass biopsy is diagnostically reliable and may provide benefit in clinical practice.
- 20 June 2026
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (12) , 6631-6635
Immediate percutaneous renal mass biopsy following cryoablation: validation of diagnostic performance and clinical outcomes
Objectives Image-guided thermal ablation is a guideline-supported treatment for small renal tumors. While biopsy is recommended, the optimal timing relative to ablation remains undefined. Pre-ablation biopsy may complicate ablation through hemorrhage, impaired target visualization, and potential tumor seeding. Post-cryoablation biopsy has been described in a small cohort of patients, but reproducibility has not been established. This study evaluated the diagnostic performance and clinical outcomes of renal mass biopsy performed immediately after cryoablation in a single session. Methods This retrospective, single-center study included patients who underwent image-guided percutaneous cryoablation followed by immediate post-ablation core needle biopsy, performed at operator discretion, between December 2018 and April 2025. After active or passive thaw and probe removal, at least two 18-gauge core biopsy samples were obtained per lesion using a coaxial needle. Specimens were formalin-fixed and reviewed by pathology. Outcomes included specimen adequacy, histopathologic diagnosis, adverse events, imaging response, and tumor recurrence or seeding. Follow-up imaging and labs were performed at 3 and 6 or 9 months, then annually. Results Twenty-six solid enhancing renal masses (mean size 2.5 cm, range 1.4–4.7 cm) in 24 patients were included. All biopsy specimens were diagnostic with histologic diagnoses including renal cell carcinoma (RCC, n = 19), oncocytoma (n = 6), and metanephric adenoma (n = 1), with RCC subtypes including clear cell, papillary, chromophobe, sarcomatoid, and mixed histology. Complications were limited to the immediate post-procedural period, with no delayed adverse events or chronic sequelae. All lesions demonstrated complete radiographic response on 3-month follow-up imaging. There were no cases of tumor recurrence or seeding observed over a median follow-up of 1,415 days. Conclusion Immediate post-cryoablation renal mass biopsy is diagnostically reliable and may provide benefit in clinical practice.
- Open Access
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5)
Yttrium-90 radioembolization treatment of metastatic thyroid carcinoma to the liver: a 3-case series
Liver metastases from well-differentiated thyroid carcinomas are rare. We report 3 patients, 1 with follicular and 2 with oncocytic thyroid cancers, treated for liver metastases with yttrium-90 radioembolization. The 2 patients with oligometastatic disease received ablative radiation doses, while 1 patient with diffuse metastatic liver disease was treated palliatively with 2 sessions of reduced nonablative radiation dose due to a large hepatopulmonary shunt fraction diagnosed at work-up. The 2 cases of oligometastatic disease had a complete local response by imaging criteria, while the third case had a pronounced local partial response, without adverse events. Future guidelines should include radioembolization as a viable option for locoregional therapy of liver metastases of differentiated thyroid cancer not responsive to radioiodine in patients that do not qualify for or refuse hepatic surgery.
- 21 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (5)
Open AccessYttrium-90 radioembolization treatment of metastatic thyroid carcinoma to the liver: a 3-case series
Liver metastases from well-differentiated thyroid carcinomas are rare. We report 3 patients, 1 with follicular and 2 with oncocytic thyroid cancers, treated for liver metastases with yttrium-90 radioembolization. The 2 patients with oligometastatic disease received ablative radiation doses, while 1 patient with diffuse metastatic liver disease was treated palliatively with 2 sessions of reduced nonablative radiation dose due to a large hepatopulmonary shunt fraction diagnosed at work-up. The 2 cases of oligometastatic disease had a complete local response by imaging criteria, while the third case had a pronounced local partial response, without adverse events. Future guidelines should include radioembolization as a viable option for locoregional therapy of liver metastases of differentiated thyroid cancer not responsive to radioiodine in patients that do not qualify for or refuse hepatic surgery.
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-11
Real-World Analysis of Multidisciplinary Roles in the Management of Hepatocellular Carcinoma: The Mayo Clinic Experience
Background: Hepatocellular carcinoma (HCC) is a complex disease best managed through multidisciplinary care, yet real-world patterns of medical specialty involvement remain poorly characterized. This study mapped specialty care pathways for HCC patients treated at the three Mayo Clinic destination medical centers. Methods: A retrospective review was performed using the Mayo Data Explorer for treatments delivered between May 2020 and May 2025. Patients with HCC were identified through diagnosis codes or hepatology consultation. Therapeutic events across interventional radiology (IR), medical oncology, transplant surgery, radiation oncology, and hepatopancreatobiliary surgery (HPBS) were analyzed descriptively by treatment line and Barcelona Clinic Liver Cancer (BCLC) stage. Results: Of 6051 HCC patients identified, 4799 met inclusion criteria. Hepatology provided consultation for 87% of patients (n=4183). For first-line treatments (n=3079), 37% received initial therapy from IR, 27% from medical oncology, 17% from transplant surgery, 10% from HPBS, and 9% from radiation oncology. IR remained the most common provider across subsequent treatment lines. Analyses were based on treatment events, and some patients contributed to multiple treatment lines. Among patients with documented BCLC stage (n = 906), IR most frequently delivered initial therapy for stages 0 and A, whereas medical oncology predominated for stages B and C. Locoregional therapies were used in 27% of BCLC C patients. Conclusion: This real-world mapping reveals IR as a procedural cornerstone within multidisciplinary HCC management, particularly for early-stage disease. Hepatology remains essential for initial patient evaluation and care coordination. Medical oncology predominates for intermediate-stage disease, while locoregional therapy continues to be used in a substantial proportion of advanced-stage cases. These findings highlight the complex and evolving role of subspecialties in the management of HCC and may inform future resource allocation and care strategies.
- 1 January 2026
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-11
Open AccessReal-World Analysis of Multidisciplinary Roles in the Management of Hepatocellular Carcinoma: The Mayo Clinic Experience
Background: Hepatocellular carcinoma (HCC) is a complex disease best managed through multidisciplinary care, yet real-world patterns of medical specialty involvement remain poorly characterized. This study mapped specialty care pathways for HCC patients treated at the three Mayo Clinic destination medical centers. Methods: A retrospective review was performed using the Mayo Data Explorer for treatments delivered between May 2020 and May 2025. Patients with HCC were identified through diagnosis codes or hepatology consultation. Therapeutic events across interventional radiology (IR), medical oncology, transplant surgery, radiation oncology, and hepatopancreatobiliary surgery (HPBS) were analyzed descriptively by treatment line and Barcelona Clinic Liver Cancer (BCLC) stage. Results: Of 6051 HCC patients identified, 4799 met inclusion criteria. Hepatology provided consultation for 87% of patients (n=4183). For first-line treatments (n=3079), 37% received initial therapy from IR, 27% from medical oncology, 17% from transplant surgery, 10% from HPBS, and 9% from radiation oncology. IR remained the most common provider across subsequent treatment lines. Analyses were based on treatment events, and some patients contributed to multiple treatment lines. Among patients with documented BCLC stage (n = 906), IR most frequently delivered initial therapy for stages 0 and A, whereas medical oncology predominated for stages B and C. Locoregional therapies were used in 27% of BCLC C patients. Conclusion: This real-world mapping reveals IR as a procedural cornerstone within multidisciplinary HCC management, particularly for early-stage disease. Hepatology remains essential for initial patient evaluation and care coordination. Medical oncology predominates for intermediate-stage disease, while locoregional therapy continues to be used in a substantial proportion of advanced-stage cases. These findings highlight the complex and evolving role of subspecialties in the management of HCC and may inform future resource allocation and care strategies.
- Open Access
- 5 October 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (1) , 37-43
Recurrent renal cell carcinoma post cryoablation secondary to splenorenal shunt thermal sink treated with venous obliteration and subsequent cryoablation
- 5 October 2025
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (1) , 37-43
Open AccessRecurrent renal cell carcinoma post cryoablation secondary to splenorenal shunt thermal sink treated with venous obliteration and subsequent cryoablation
- 22 April 2024
- Published by Elsevier
- p. 75-78
Other product types
- 22 April 2024
- Published by Elsevier
- p. 53-57
Device testing
- Open Access
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (30) , eaba5672
Increased PIP3 activity blocks nanoparticle mRNA delivery
PIP3, a bioactive lipid upstream of the PI3K/AKT/mTOR pathway, decreased protein translated from nanoparticle-delivered mRNA.
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (30) , eaba5672
Open AccessIncreased PIP3 activity blocks nanoparticle mRNA delivery
PIP3, a bioactive lipid upstream of the PI3K/AKT/mTOR pathway, decreased protein translated from nanoparticle-delivered mRNA.
- 19 November 2019
- Published by Wiley in Advanced Materials
- Vol. 32 (1) , e1904905
Mild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery
Clinical mRNA delivery remains challenging, in large part because how physiology alters delivery in vivo remains underexplored. For example, mRNA delivered by lipid nanoparticles (LNPs) is being considered to treat inflammation, but whether inflammation itself changes delivery remains understudied. Relationships between immunity, endocytosis, and mRNA translation lead to hypothesize that toll‐like receptor 4 (TLR4) activation reduced LNP‐mediated mRNA delivery. Therefore, LNP uptake, endosomal escape, and mRNA translation with and without TLR4 activation are quantified. In vivo DNA barcoding is used to discover a novel LNP that delivers mRNA to Kupffer cells at clinical doses; unlike most LNPs, this LNP does not preferentially target hepatocytes. TLR4 activation blocks mRNA translation in all tested cell types, without reducing LNP uptake; inhibiting TLR4 or its downstream effector protein kinase R improved delivery. The discrepant effects of TLR4 on i) LNP uptake and ii) translation suggests TLR4 activation can “override” LNP targeting, even after mRNA is delivered into target cells. Given near‐future clinical trials using mRNA to modulate inflammation, this highlights the need to understand inflammatory signaling in on‐ and off‐target cells. More generally, this suggests an LNP which delivers mRNA to one inflammatory disease may not deliver mRNA to another.
- 19 November 2019
- Published by Wiley in Advanced Materials
- Vol. 32 (1) , e1904905
Mild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery
Clinical mRNA delivery remains challenging, in large part because how physiology alters delivery in vivo remains underexplored. For example, mRNA delivered by lipid nanoparticles (LNPs) is being considered to treat inflammation, but whether inflammation itself changes delivery remains understudied. Relationships between immunity, endocytosis, and mRNA translation lead to hypothesize that toll‐like receptor 4 (TLR4) activation reduced LNP‐mediated mRNA delivery. Therefore, LNP uptake, endosomal escape, and mRNA translation with and without TLR4 activation are quantified. In vivo DNA barcoding is used to discover a novel LNP that delivers mRNA to Kupffer cells at clinical doses; unlike most LNPs, this LNP does not preferentially target hepatocytes. TLR4 activation blocks mRNA translation in all tested cell types, without reducing LNP uptake; inhibiting TLR4 or its downstream effector protein kinase R improved delivery. The discrepant effects of TLR4 on i) LNP uptake and ii) translation suggests TLR4 activation can “override” LNP targeting, even after mRNA is delivered into target cells. Given near‐future clinical trials using mRNA to modulate inflammation, this highlights the need to understand inflammatory signaling in on‐ and off‐target cells. More generally, this suggests an LNP which delivers mRNA to one inflammatory disease may not deliver mRNA to another.
- 12 February 2019
- Published by Wiley in Advanced Materials
- Vol. 31 (14) , e1807748
Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses
Using mRNA to produce therapeutic proteins is a promising approach to treat genetic diseases. However, systemically delivering mRNA to cell types besides hepatocytes remains challenging. Fast identification of nanoparticle delivery (FIND) is a DNA barcode‐based system designed to measure how over 100 lipid nanoparticles (LNPs) deliver mRNA that functions in the cytoplasm of target cells in a single mouse. By using FIND to quantify how 75 chemically distinct LNPs delivered mRNA to 28 cell types in vivo, it is found that an LNP formulated with oxidized cholesterol and no targeting ligand delivers Cre mRNA, which edits DNA in hepatic endothelial cells and Kupffer cells at 0.05 mg kg−1. Notably, the LNP targets liver microenvironmental cells fivefold more potently than hepatocytes. The structure of the oxidized cholesterols added to the LNP is systematically varied to show that the position of the oxidative modification may be important; cholesterols modified on the hydrocarbon tail associated with sterol ring D tend to outperform cholesterols modified on sterol ring B. These data suggest that LNPs formulated with modified cholesterols can deliver gene‐editing mRNA to the liver microenvironment at clinically relevant doses.
- 12 February 2019
- Published by Wiley in Advanced Materials
- Vol. 31 (14) , e1807748
Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses
Using mRNA to produce therapeutic proteins is a promising approach to treat genetic diseases. However, systemically delivering mRNA to cell types besides hepatocytes remains challenging. Fast identification of nanoparticle delivery (FIND) is a DNA barcode‐based system designed to measure how over 100 lipid nanoparticles (LNPs) deliver mRNA that functions in the cytoplasm of target cells in a single mouse. By using FIND to quantify how 75 chemically distinct LNPs delivered mRNA to 28 cell types in vivo, it is found that an LNP formulated with oxidized cholesterol and no targeting ligand delivers Cre mRNA, which edits DNA in hepatic endothelial cells and Kupffer cells at 0.05 mg kg−1. Notably, the LNP targets liver microenvironmental cells fivefold more potently than hepatocytes. The structure of the oxidized cholesterols added to the LNP is systematically varied to show that the position of the oxidative modification may be important; cholesterols modified on the hydrocarbon tail associated with sterol ring D tend to outperform cholesterols modified on sterol ring B. These data suggest that LNPs formulated with modified cholesterols can deliver gene‐editing mRNA to the liver microenvironment at clinically relevant doses.
- 5 November 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (49) , 17095-17105
Nanoparticles That Deliver RNA to Bone Marrow Identified by in Vivo Directed Evolution
Bone marrow endothelial cells (BMECs) regulate their microenvironment, which includes hematopoietic stem cells. This makes BMECs an important target cell type for siRNA or gene editing (e.g., CRISPR) therapies. However, siRNA and sgRNA have not been delivered to BMECs using systemically administered nanoparticles. Given that in vitro nanoparticle screens have not identified nanoparticles with BMEC tropism, we developed a system to quantify how >100 different nanoparticles deliver siRNA in a single mouse. This is the first barcoding system capable of quantifying functional cytosolic siRNA delivery (where the siRNA drug is active), distinguishing it from in vivo screens that quantify biodistribution (where the siRNA drug went). Combining this approach with bioinformatics, we performed in vivo directed evolution, and identified BM1, a lipid nanoparticle (LNP) that delivers siRNA and sgRNA to BMECs. Interestingly, chemical analysis revealed BMEC tropism was not related to LNP size; tropism changed with the structure of poly(ethylene glycol), as well as the presence of cholesterol. These results suggest that significant changes to vascular targeting can be imparted to a LNP by making simple changes to its chemical composition, rather than using active targeting ligands. BM1 is the first nanoparticle to efficiently deliver siRNA and sgRNA to BMECs in vivo, demonstrating that this functional in vivo screen can identify nanoparticles with novel tropism in vivo. More generally, in vivo screening may help reveal the complex relationship between nanoparticle structure and tropism, thereby helping scientists understand how simple chemical changes control nanoparticle targeting.
- 5 November 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (49) , 17095-17105
Nanoparticles That Deliver RNA to Bone Marrow Identified by in Vivo Directed Evolution
Bone marrow endothelial cells (BMECs) regulate their microenvironment, which includes hematopoietic stem cells. This makes BMECs an important target cell type for siRNA or gene editing (e.g., CRISPR) therapies. However, siRNA and sgRNA have not been delivered to BMECs using systemically administered nanoparticles. Given that in vitro nanoparticle screens have not identified nanoparticles with BMEC tropism, we developed a system to quantify how >100 different nanoparticles deliver siRNA in a single mouse. This is the first barcoding system capable of quantifying functional cytosolic siRNA delivery (where the siRNA drug is active), distinguishing it from in vivo screens that quantify biodistribution (where the siRNA drug went). Combining this approach with bioinformatics, we performed in vivo directed evolution, and identified BM1, a lipid nanoparticle (LNP) that delivers siRNA and sgRNA to BMECs. Interestingly, chemical analysis revealed BMEC tropism was not related to LNP size; tropism changed with the structure of poly(ethylene glycol), as well as the presence of cholesterol. These results suggest that significant changes to vascular targeting can be imparted to a LNP by making simple changes to its chemical composition, rather than using active targeting ligands. BM1 is the first nanoparticle to efficiently deliver siRNA and sgRNA to BMECs in vivo, demonstrating that this functional in vivo screen can identify nanoparticles with novel tropism in vivo. More generally, in vivo screening may help reveal the complex relationship between nanoparticle structure and tropism, thereby helping scientists understand how simple chemical changes control nanoparticle targeting.